| abstract |
Novel HDL mimetic polypeptides are disclosed, particularly Apo A-1 Carnivora/Sapien polypeptides. Nucleic acids coding for the Apo A-1 Carnivora/Sapien polypeptides are also disclosed, as are pharmaceutical formulations comprising the disclosed polypeptides and pharmaceutical formulations comprising the disclosed nucleic acids. Finally, methods to prevent, treat, ameliorate, and diagnose atherosclerosis and related disorders, in mammals, such as humans, are disclosed. |